Insmed (NASDAQ:INSM) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.
Other equities research analysts have also recently issued reports about the company. Zacks Investment Research cut Insmed from a “buy” rating to a “hold” rating in a research note on Friday, January 12th. Robert W. Baird reissued a “positive” rating and issued a $42.00 target price (up from $32.00) on shares of Insmed in a research note on Thursday, January 4th. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Insmed in a research note on Thursday, January 4th. ValuEngine raised Insmed from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Credit Suisse Group initiated coverage on Insmed in a report on Wednesday, January 17th. They set a “neutral” rating and a $31.00 price target on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $36.67.
Shares of Insmed (NASDAQ:INSM) opened at $26.23 on Friday. Insmed has a 12 month low of $11.49 and a 12 month high of $33.94. The company has a market capitalization of $2,010.00, a price-to-earnings ratio of -9.14 and a beta of 1.13. The company has a quick ratio of 8.72, a current ratio of 8.72 and a debt-to-equity ratio of 0.15.
Several large investors have recently made changes to their positions in INSM. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Insmed by 137.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,662 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 2,698 shares in the last quarter. Public Employees Retirement Association of Colorado bought a new position in shares of Insmed during the fourth quarter valued at $188,000. Prudential Financial Inc. bought a new position in shares of Insmed during the third quarter valued at $232,000. Jefferies Group LLC bought a new position in shares of Insmed during the fourth quarter valued at $245,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of Insmed during the third quarter valued at $256,000. 98.15% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3256439/insmed-insm-stock-rating-upgraded-by-bidaskclub.html.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.